Header Logo

Connection

COLIN P DINNEY to Carcinoma, Transitional Cell

Back to Details
This is a "connection" page, showing publications COLIN P DINNEY has written about Carcinoma, Transitional Cell.
COLIN P DINNEY
Connection Strength
10.869
Carcinoma, Transitional Cell
  1. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019.
    View in: PubMed
    Score: 0.278
  2. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7.
    View in: PubMed
    Score: 0.276
  3. Phase I trial of intravesical recombinant adenovirus mediated interferon-a2b formulated in Syn3 for Bacillus Calmette-Gu?rin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep; 190(3):850-6.
    View in: PubMed
    Score: 0.269
  4. The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition. Cancer Prev Res (Phila). 2009 Dec; 2(12):1001-2.
    View in: PubMed
    Score: 0.214
  5. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):335-44.
    View in: PubMed
    Score: 0.214
  6. Urological cancers. Preface. Cancer Metastasis Rev. 2009 Dec; 28(3-4):267.
    View in: PubMed
    Score: 0.214
  7. High risk populations and cystectomy outcomes. J Urol. 2009 Jul; 182(1):10-1.
    View in: PubMed
    Score: 0.206
  8. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 2008 Sep; 180(3):1146-53.
    View in: PubMed
    Score: 0.195
  9. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep. 2008 Jan; 9(1):55-61.
    View in: PubMed
    Score: 0.188
  10. Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. Cancer Metastasis Rev. 2007 Dec; 26(3-4):623-34.
    View in: PubMed
    Score: 0.186
  11. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008 Jan; 179(1):353-8.
    View in: PubMed
    Score: 0.186
  12. Targeted therapies in bladder cancer--an update. Urol Oncol. 2007 Sep-Oct; 25(5):433-8.
    View in: PubMed
    Score: 0.183
  13. High-grade T1 bladder cancer at the ureterovesical junction. Curr Urol Rep. 2007 Mar; 8(2):104-7.
    View in: PubMed
    Score: 0.177
  14. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol. 2006 Aug; 176(2):787-92.
    View in: PubMed
    Score: 0.170
  15. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun; 175(6):2058-62.
    View in: PubMed
    Score: 0.168
  16. Urothelial cancer biomarkers for detection and surveillance. Urology. 2006 Mar; 67(3 Suppl 1):25-33; discussion 33-4.
    View in: PubMed
    Score: 0.165
  17. Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am. 2005 May; 32(2):239-46, vii.
    View in: PubMed
    Score: 0.156
  18. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004 Feb; 171(2 Pt 1):570-4.
    View in: PubMed
    Score: 0.143
  19. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S85-104.
    View in: PubMed
    Score: 0.137
  20. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003 Jun 15; 21(12):2247-53.
    View in: PubMed
    Score: 0.137
  21. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.
    View in: PubMed
    Score: 0.134
  22. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol. 2023 01; 209(1):140-149.
    View in: PubMed
    Score: 0.131
  23. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
    View in: PubMed
    Score: 0.129
  24. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.
    View in: PubMed
    Score: 0.124
  25. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res. 2001 Sep; 7(9):2840-53.
    View in: PubMed
    Score: 0.121
  26. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology. 2001 May; 57(5):852-9.
    View in: PubMed
    Score: 0.118
  27. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Gu?rin Therapy Outcomes. Eur Urol Oncol. 2022 06; 5(3):347-356.
    View in: PubMed
    Score: 0.118
  28. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 09; 206(3):548-557.
    View in: PubMed
    Score: 0.118
  29. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol. 2001 Apr; 165(4):1152-7.
    View in: PubMed
    Score: 0.117
  30. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 11; 128(5):568-574.
    View in: PubMed
    Score: 0.116
  31. Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urol Oncol. 2021 05; 39(5):301.e17-301.e28.
    View in: PubMed
    Score: 0.116
  32. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep. 2001 Jan-Feb; 8(1):9-15.
    View in: PubMed
    Score: 0.115
  33. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000 Dec; 6(12):4866-73.
    View in: PubMed
    Score: 0.115
  34. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000 Dec; 6(12):4874-84.
    View in: PubMed
    Score: 0.115
  35. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
    View in: PubMed
    Score: 0.114
  36. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214.
    View in: PubMed
    Score: 0.112
  37. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000 Jul; 6(7):2635-43.
    View in: PubMed
    Score: 0.112
  38. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000 Apr 15; 60(8):2290-9.
    View in: PubMed
    Score: 0.110
  39. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
    View in: PubMed
    Score: 0.107
  40. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1999 Sep; 162(3 Pt 1):710-4.
    View in: PubMed
    Score: 0.105
  41. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Dec; 37(12):2691-2698.
    View in: PubMed
    Score: 0.102
  42. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26.
    View in: PubMed
    Score: 0.101
  43. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999 Feb; 5(2):257-65.
    View in: PubMed
    Score: 0.101
  44. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol. 1998 Oct; 160(4):1285-90.
    View in: PubMed
    Score: 0.099
  45. Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. J Endourol. 2018 09 12; 32(9):806-811.
    View in: PubMed
    Score: 0.098
  46. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol. 2019 Jan; 37(1):51-60.
    View in: PubMed
    Score: 0.098
  47. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.096
  48. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998 Mar; 159(3):792-5.
    View in: PubMed
    Score: 0.095
  49. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 02; 121(2):244-251.
    View in: PubMed
    Score: 0.092
  50. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.091
  51. Dose dense MVAC prior to radical cystectomy: a real-world experience. World J Urol. 2017 Nov; 35(11):1729-1736.
    View in: PubMed
    Score: 0.090
  52. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506.
    View in: PubMed
    Score: 0.090
  53. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res. 1997 Feb; 3(2):161-8.
    View in: PubMed
    Score: 0.088
  54. Radical cystectomy for stage T3b bladder cancer. Semin Urol Oncol. 1996 May; 14(2):73-80.
    View in: PubMed
    Score: 0.084
  55. The role of chemotherapy in the management of the patient with T3b bladder cancer. Semin Urol Oncol. 1996 May; 14(2):81-5.
    View in: PubMed
    Score: 0.084
  56. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620.
    View in: PubMed
    Score: 0.083
  57. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol. 1996 Feb; 155(2):501-3.
    View in: PubMed
    Score: 0.082
  58. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol. 1995 Oct; 154(4):1532-8.
    View in: PubMed
    Score: 0.080
  59. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
    View in: PubMed
    Score: 0.080
  60. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. J Interferon Cytokine Res. 1995 Jun; 15(6):585-92.
    View in: PubMed
    Score: 0.078
  61. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila). 2015 Jul; 8(7):607-13.
    View in: PubMed
    Score: 0.078
  62. Management of transitional cell carcinoma involving von Brunn's nests. J Urol. 1995 Mar; 153(3 Pt 2):944-9.
    View in: PubMed
    Score: 0.077
  63. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
    View in: PubMed
    Score: 0.076
  64. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug; 32(6):826-32.
    View in: PubMed
    Score: 0.073
  65. Therapy and prognosis for male anterior urethral carcinoma: an update. Urology. 1994 Apr; 43(4):506-14.
    View in: PubMed
    Score: 0.072
  66. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72.
    View in: PubMed
    Score: 0.072
  67. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9.
    View in: PubMed
    Score: 0.072
  68. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol. 2013 Nov-Dec; 39(6):817-22.
    View in: PubMed
    Score: 0.070
  69. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013 May; 189(5):1656-61.
    View in: PubMed
    Score: 0.066
  70. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7.
    View in: PubMed
    Score: 0.065
  71. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int. 2012 Dec; 110(11 Pt B):E590-5.
    View in: PubMed
    Score: 0.064
  72. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol. 2012 Dec; 30(6):753-9.
    View in: PubMed
    Score: 0.061
  73. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. 2012 Nov-Dec; 30(6):821-4.
    View in: PubMed
    Score: 0.058
  74. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7.
    View in: PubMed
    Score: 0.058
  75. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21.
    View in: PubMed
    Score: 0.058
  76. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
    View in: PubMed
    Score: 0.058
  77. Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol. 2011 Jan; 185(1):79-83.
    View in: PubMed
    Score: 0.057
  78. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol. 2010 Oct; 195(4):959-65.
    View in: PubMed
    Score: 0.057
  79. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2010 Oct; 3(10):1235-45.
    View in: PubMed
    Score: 0.057
  80. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010 Sep; 184(3):888-94.
    View in: PubMed
    Score: 0.056
  81. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
    View in: PubMed
    Score: 0.056
  82. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34.
    View in: PubMed
    Score: 0.056
  83. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun; 183(6):2165-70.
    View in: PubMed
    Score: 0.055
  84. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol. 2011 Mar-Apr; 29(2):157-61.
    View in: PubMed
    Score: 0.055
  85. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol. 2010 Mar; 183(3):929-34.
    View in: PubMed
    Score: 0.054
  86. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93.
    View in: PubMed
    Score: 0.054
  87. Management of urethral recurrence after orthotopic urinary diversion. BJU Int. 2010 Jul; 106(1):56-61.
    View in: PubMed
    Score: 0.054
  88. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.053
  89. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52.
    View in: PubMed
    Score: 0.049
  90. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008 Oct 01; 100(19):1401-11.
    View in: PubMed
    Score: 0.049
  91. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008 Jul; 88(7):694-721.
    View in: PubMed
    Score: 0.048
  92. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86.
    View in: PubMed
    Score: 0.047
  93. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.047
  94. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007 Dec; 178(6):2302-6; discussion 2307.
    View in: PubMed
    Score: 0.046
  95. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology. 2007 Sep; 70(3):473-6.
    View in: PubMed
    Score: 0.046
  96. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9.
    View in: PubMed
    Score: 0.046
  97. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug; 70(2):252-6.
    View in: PubMed
    Score: 0.046
  98. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007 Jul 01; 110(1):62-7.
    View in: PubMed
    Score: 0.045
  99. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80.
    View in: PubMed
    Score: 0.043
  100. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006 Mar; 175(3 Pt 1):881-5.
    View in: PubMed
    Score: 0.041
  101. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006 Mar; 67(3):466-71.
    View in: PubMed
    Score: 0.041
  102. The pathology of bladder cancer. Urology. 2006 Mar; 67(3 Suppl 1):11-7; discussion 17-8.
    View in: PubMed
    Score: 0.041
  103. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. 2004 Dec 15; 64(24):8973-9.
    View in: PubMed
    Score: 0.038
  104. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Curr Opin Urol. 2004 Sep; 14(5):295-300.
    View in: PubMed
    Score: 0.037
  105. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res. 2004 Jul 01; 64(13):4601-10.
    View in: PubMed
    Score: 0.037
  106. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am. 2003 Nov; 30(4):791-802.
    View in: PubMed
    Score: 0.035
  107. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol. 2003 Jun; 169(6):2113-7.
    View in: PubMed
    Score: 0.034
  108. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.
    View in: PubMed
    Score: 0.028
  109. The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am. 2000 Feb; 27(1):103-13, ix.
    View in: PubMed
    Score: 0.027
  110. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol. 1999 May; 20(5):285-90.
    View in: PubMed
    Score: 0.026
  111. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998 Feb 15; 58(4):808-14.
    View in: PubMed
    Score: 0.024
  112. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol. 1998 Feb; 159(2):394-8.
    View in: PubMed
    Score: 0.024
  113. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol. 1997 Sep; 158(3 Pt 1):806-11.
    View in: PubMed
    Score: 0.023
  114. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1997 Jan 01; 37(1):41-9.
    View in: PubMed
    Score: 0.022
  115. DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol. 1996 May; 9(5):571-8.
    View in: PubMed
    Score: 0.021
  116. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology. 1996 Mar; 47(3):305-10.
    View in: PubMed
    Score: 0.021
  117. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):331-40.
    View in: PubMed
    Score: 0.020
  118. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer. 1994 Nov 15; 74(10):2819-27.
    View in: PubMed
    Score: 0.019
  119. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer. 2013 Jun 11; 108(11):2372-80.
    View in: PubMed
    Score: 0.017
  120. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005 Nov 15; 65(22):10524-35.
    View in: PubMed
    Score: 0.010
  121. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 2003 Aug 01; 9(8):3167-75.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.